MedImmune has announced changes at the top of the company to help it continue in its role as the global biologics unit for AstraZeneca (AZ).
Andrew Skibo has joined the company as senior vice president, engineering. He will be responsible for overseeing large-scale capital projects at all of MedImmune’s facilities, including sites in California, Pennsylvania, Maryland, and the UK, as well as the ongoing construction of the company’s antibody-manufacturing facilities in Frederick, Maryland.
And Dr JoAnn Suzich, a 19-year veteran of the company, has been promoted to vice president, research and development, infectious disease.
In addition, MedImmune has announced that it has established a new site leadership team at its Cambridge facilities as a part of the plan to integrate the former Cambridge Antibody Technology (CAT) organisation into AZ’s new global biologics unit.
David Mott, MedImmune chief executive officer and president, said: “As MedImmune supports AZ in its efforts to build a major international presence in the research, development and manufacture of biological therapeutics, it’s critical that we continue to expand the depth of our leadership capabilities.
“I am pleased with the high-calibre scientific and technical talent MedImmune continues to hire and retain as we strive to create the most productive and successful biotech business, with benefits to patients, shareholders and employees worldwide.”
Copyright © PA Business 2007